Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

JADE101

Other · developed by Jade Biosciences

Phase 3 Most advanced trial
JBIO Developer
1 Registered trials

What is JADE101?

JADE101 is a sterile solution given by subcutaneous injection. It is being studied in IgA nephropathy, a form of glomerulonephritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Renal & urology
Developer
Jade Biosciences, Inc. (JBIO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07902817 Phase 3 IgA Nephropathy (IgAN) Recruiting JBIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

IgA Nephropathy (IgAN)

More from Jade Biosciences

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the JBIO page.

Follow JBIO, the company behind JADE101

See JBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JBIO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.